UnknownNot applicableNCT01902238

EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study

Studying Neuroendocrine neoplasm of pancreas

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Asan Medical Center
Principal Investigator: Do Hyun Park, MD, PhD
Asan Medical Center, Seoul, Korea, Republic of
Intervention: EUS-guided ethanol-lipiodol mixture ablation(procedure)
Enrollment: 34 enrolled
Eligibility: 18 years · All sexes
Timeline: 2013 – 2017

Study locations (1)

Asan Medical Center, Seoul, South Korea

Collaborators

Dankook University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01902238 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm of pancreas →

← Back to all trials